<DOC>
	<DOCNO>NCT02281916</DOCNO>
	<brief_summary>This multicenter phase 2 clinical trial design assess safety P28GST ( protein 28 Kd glutathion S Transferrase ) , aim control inflammation moderate Crohn 's Disease ( CD ) , intestinal resection surgery . P28GST parasite enzyme molecule Schistosoma potent immunogenic anti-oxidant property . Based experimental evidence anti-inflammatory property , investigator hypothesize administration P28GST could protect recurrence intestinal resection surgery CD .</brief_summary>
	<brief_title>Safety Study P28GST Treatment Crohn 's Disease Patients</brief_title>
	<detailed_description>To carry study , 24 moderate CD patient enrol safety phase 2a study . CD patient include intestinal resection surgery moderate Crohn 's Disease ( CD ) . Drug therapy consist 3 injection 100 µg P28GST within 3 month ( one injection per month ) . The main objective study follow-up monthly rate seriousness adverse event one year . Secondary objective control immunologic inflammatory blood tissue marker , appearance clinical recurrence assess CDAI ( Crohn Disease Activity Index ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects age ≥18 year inclusion . Subjects ileal ileocolic CD without fistula Subjects operate CDAI score &lt; 220 concomitant treatment except salicylate Women child bear potential must negative pregnancy prior study enrolment contraceptive mean : female childbearing potential well male require use adequate contraceptive method 6 month start inclusion , ; e 4 month 3rd injection . No tobacco consumption ( end date tobacco consumption 8 day surgery ) . Signed consent form French social security coverage . Subject use azathioprine , antiTNF ( Tumor Necrosis Factor ) , methotrexate , Vedolizumab , Ustekinumab immunosuppressors 8 week first injection P28GST Subject use corticosteroid 15 day first injection P28GST Subject history vaccine hyper sensitivity allergy . Subject clinical manifestation determine investigator Subject wih AIDS , B C hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Crohn disease</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Helminth antigen</keyword>
</DOC>